Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18372671 | 0.88 | CYP2D6 (0.37) | STAT3CYP2D6CYP1A2ALDH1A1KMT2A | |
| SCHEMBL17709993 | 0.86 | STAT3 (0.39) | STAT3CYP2D6CYP1A2GAAALDH1A1 | |
| SCHEMBL16797552 | 0.85 | CA12 (0.38) | STAT3CYP2D6CYP1A2GAAALDH1A1 | |
| SCHEMBL962353 | 0.85 | CYP2D6 (0.39) | STAT3CYP2D6CYP1A2GAAALDH1A1 | |
| SCHEMBL31715621 | 0.84 | PTGS1 (0.41) | STAT3CYP2D6CYP1A2GAAALDH1A1 | |
| SCHEMBL1864018 | 0.84 | PLCG1 (0.38) | CYP2D6ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19029520 | 0.84 | FFAR2 (0.45) | GAAALDH1A1KMT2ACA9CA2 | |
| SCHEMBL22660615 | 0.83 | STAT3 (0.40) | STAT3CYP2D6CYP1A2GAAALDH1A1 | |
| SCHEMBL22660613 | 0.83 | STAT3 (0.40) | STAT3CYP2D6CYP1A2GAAALDH1A1 | |
| SCHEMBL25607614 | 0.83 | STAT3 (0.37) | STAT3CYP2D6CYP1A2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516061-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-01-06 | — | — | US | disclosed |
| EP-4520395-A2 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2025-03-12 | — | — | EP | disclosed |
| US-20250026755-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-3856742-B1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2024-10-02 | — | — | EP | disclosed |
| US-12024516-B2 | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024516-B2 | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| EP-4308562-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-11858933-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858933-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-8232269-B2 | Amide compounds useful in therapy | PFIZER INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2350017-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100249091-A1 | Amide Compounds Useful in Therapy | GIBSON KARL RICHARD | 2010-09-30 | — | — | US | disclosed |
| US-20100249091-A1 | Amide Compounds Useful in Therapy | GIBSON KARL RICHARD | 2010-09-30 | — | — | US | disclosed |
| WO-2010032200-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
| EP-2142555-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
| WO-2004032834-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249091-A1 | Amide Compounds Useful in Therapy | PTGER3, PTGER1, PTGER2 | STAT3 1803/4885CYP2D6 472/4885CYP1A2 421/4885 |
| US-11858933-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | JAK1, JAK2, JAK3 | STAT3 35/4885CYP2D6 2963/4885CYP1A2 1867/4885 |
| US-12024516-B2 | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | JAK1, JAK2, JAK3 | STAT3 35/4885CYP2D6 2963/4885CYP1A2 1867/4885 |
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | STAT3 1908/4885CYP2D6 1009/4885CYP1A2 389/4885 |
| US-20250026755-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK2, JAK3 | STAT3 35/4885CYP2D6 2963/4885CYP1A2 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.